PAT Implementation Will Depend On FDA-Industry Collaboration, AstraZeneca Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry must be willing to discuss unfavorable data with FDA for process analytical technology to work, AstraZeneca CMC Director Robert Timko says. FDA is working to ensure consistency between its review centers and field offices as part of the PAT implementation process.